BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 19951140)

  • 1. Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.
    Thaker NG; Pollack IF
    Expert Rev Neurother; 2009 Dec; 9(12):1815-36. PubMed ID: 19951140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted molecular therapy of malignant gliomas.
    Kesari S; Ramakrishna N; Sauvageot C; Stiles CD; Wen PY
    Curr Neurol Neurosci Rep; 2005 May; 5(3):186-97. PubMed ID: 15865884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecularly targeted therapies for glioma.
    Yamanaka R; Saya H
    Ann Neurol; 2009 Dec; 66(6):717-29. PubMed ID: 20035507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Newton HB
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecularly targeted therapy for malignant glioma.
    Sathornsumetee S; Reardon DA; Desjardins A; Quinn JA; Vredenburgh JJ; Rich JN
    Cancer; 2007 Jul; 110(1):13-24. PubMed ID: 17520692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targeting for malignant gliomas (Review).
    Kondo Y; Hollingsworth EF; Kondo S
    Int J Oncol; 2004 May; 24(5):1101-9. PubMed ID: 15067331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy for malignant glioma based on PTEN status.
    Gonzalez J; de Groot J
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1767-79. PubMed ID: 18983237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.
    Newton HB
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):105-28. PubMed ID: 14748662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in Targeted Therapy for Glioma.
    Lin L; Cai J; Jiang C
    Curr Med Chem; 2017; 24(13):1365-1381. PubMed ID: 28019637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
    Lefranc F; Rynkowski M; DeWitte O; Kiss R
    Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies for malignant glioma: progress and potential.
    Mercer RW; Tyler MA; Ulasov IV; Lesniak MS
    BioDrugs; 2009; 23(1):25-35. PubMed ID: 19344189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas.
    Fernández MB; Alonso VP
    Childs Nerv Syst; 2016 Oct; 32(10):1939-45. PubMed ID: 27659836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging molecular therapies for brain tumors.
    Van Meir EG; Bellail A; Phuphanich S
    Semin Oncol; 2004 Apr; 31(2 Suppl 4):38-46. PubMed ID: 15124133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The challenges and the promise of molecular targeted therapy in malignant gliomas.
    Wang H; Xu T; Jiang Y; Xu H; Yan Y; Fu D; Chen J
    Neoplasia; 2015 Mar; 17(3):239-55. PubMed ID: 25810009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.
    Grossauer S; Koeck K; Murphy NE; Meyers ID; Daynac M; Truffaux N; Truong AY; Nicolaides TP; McMahon M; Berger MS; Phillips JJ; James CD; Petritsch CK
    Oncotarget; 2016 Nov; 7(46):75839-75853. PubMed ID: 27713119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updated Insights on EGFR Signaling Pathways in Glioma.
    Oprita A; Baloi SC; Staicu GA; Alexandru O; Tache DE; Danoiu S; Micu ES; Sevastre AS
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy for malignant glioma patients: lessons learned and the road ahead.
    Huang TT; Sarkaria SM; Cloughesy TF; Mischel PS
    Neurotherapeutics; 2009 Jul; 6(3):500-12. PubMed ID: 19560740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New medical strategies for midgut carcinoids.
    Nilsson O; Arvidsson Y; Johanson V; Forssell-Aronsson E; Ahlman H
    Anticancer Agents Med Chem; 2010 Mar; 10(3):250-69. PubMed ID: 20406194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.